Akari Therapeutics (AKTX) Treasury Shares (2022 - 2025)

Akari Therapeutics has disclosed Treasury Shares across 4 years of filings, most recently posting $1465.0 for Q4 2025.

• Treasury Shares for Q4 2025 came in at $1465.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $1465.0 (changed N/A YoY), and the FY2025 annual result was $1465.0, changed N/A from the prior year.
• Treasury Shares came in at $1465.0 for Q4 2025 at Akari Therapeutics, down from $251.8 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $386.0 million in Q4 2023 to a low of $1465.0 in Q4 2025.
• The 4-year median for Treasury Shares is $251.8 million (2024), against an average of $199.9 million.
• Peak annual rise in Treasury Shares reached 1697.2% in 2023, while the deepest fall reached 1697.2% in 2023.
• Akari Therapeutics' Treasury Shares stood at $21.5 million in 2022, then surged by 1697.2% to $386.0 million in 2023, then plunged by 34.75% to $251.8 million in 2024, then slumped by 100.0% to $1465.0 in 2025.
• The last three Treasury Shares figures came in at $1465.0 (Q4 2025), $251.8 million (Q3 2024), and $251.8 million (Q2 2024), per Business Quant data.